MedTrace Logo

Effect of Theophylline in Pseudohypoparathyroidism

NCT03718403 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-07-22

No results posted yet for this study

Summary

The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.

Conditions

  • PHP Ia
  • PHP IB
  • Php1C

Interventions

DRUG

Theophylline

Theophylline will be given to maintain a peak level between 10-15 mcg/mL

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • AMITA SHARMA, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2030-04-10
Completion
2032-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03718403 on ClinicalTrials.gov